Hiroya Taniguchi

Presentation(s):

• SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

  Friday, July 1, 2022
  08:42 – 08:50